Nepafenac Ophthalmic Dosage

Medically reviewed by Drugs.com. Last updated on Jul 6, 2023.

Usual Adult Dose for Postoperative Ocular Inflammation

0.1% suspension: 1 drop applied to the affected eye 3 times a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period

0.3% suspension: 1 drop applied to the affected eye once a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period; an additional drop should be administered 30 to 120 minutes before surgery

Comments:

• This drug may be administered in conjunction with other topical ophthalmic drugs such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.
• If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Use: Treatment of pain and inflammation associated with cataract surgery

Usual Pediatric Dose for Postoperative Ocular Inflammation

10 years or older:
0.1% suspension: 1 drop applied to the affected eye 3 times a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period

0.3% suspension: 1 drop applied to the affected eye once a day beginning 1 day before cataract surgery, continued the day of surgery and through the first 2 weeks of the postoperative period; an additional drop should be administered 30 to 120 minutes before surgery

Comments:

• This drug may be administered in conjunction with other topical ophthalmic drugs such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.
• If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Use: Treatment of pain and inflammation associated with cataract surgery

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component, other NSAIDs, or any of the ingredients

Safety and efficacy have not been established in patients younger than 10 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• The bottle should be shaken well prior to administration.
• This drug is for ophthalmic use only; it should not be swallowed or injected.
• Nasolacrimal occlusion and instructing the patient to gently close the eyelid following instillation may reduce systemic absorption of this drug.
• Care should be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.

Storage requirements:

• Protect from light and store below 25C.
• Bottle should be kept tightly closed when not in use.

Patient advice:

• Patients should be advised not to swallow this drug.
• Patients should be told to avoid sunlight during treatment.
• Patients should be instructed to shake the bottle well before use.
• This drug may cause temporary changes in vision; patients should avoid driving or operating machinery until their vision clears.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer